Our findings indicate that SNPs in KRT81 and XPO5 could prove to be useful biomarkers for individualizing therapy in NSCLC patients and that KRT81 may be a novel immunohistochemical marker of squamous cell carcinoma, providing a new diagnostic tool to be used in therapeutic decision-making. The gene discussed is XPO5; the disease is non-small cell lung carcinoma.